

**THE FOLLOWING DRUGS WILL BE REVIEWED AT THE
DRUG UTILIZATION REVIEW BOARD MEETING**

March 26, 2015

Georgia Department of Community Health

This list may change at any time. If a supplemental rebate class is not listed below, the class will be reviewed at the June 4th meeting. In addition, some of the new drugs and supplemental rebate classes listed below may also be moved for review at the June 4th meeting that will be determined by the end of February; thus, these manufacturers can present at the February Manufacturers' Forum and will not need to present again at the April Manufacturers' Forum. Information on the Manufacturers' Forum can be found at <http://dch.georgia.gov/durb-meeting-information>. Please check back frequently for updates.

New Drugs for Review

Aptiom

Cycloset

Jardiance

Tanzeum

Trulicity

Anoro Ellipta/Incruse Ellipta

Striverdi Respimat

Otezla

Stelara

Zontivity

Harvoni

Viekira

Plegridy

Uceris

Supplemental Rebate Classes for Review

Attention Deficit Hyperactivity Disorder (ADHD) Agents

Aminoglycosides for Cystic Fibrosis
Opioid Agonist, Partial Agonists
Analgesics, Opioid
Androgens, Anabolic
Anticoagulants
Anticonvulsants
Antidepressants
Antidiabetics, Insulin
Antidiabetics, Non-insulin
Antiemetics
Antihemophilic Products
Antihistamines
Antihyperlipidemics
Antihypertensives, Angiotensin Receptor Blocker/Calcium Channel Blocker Combinations
Antihypertensives, Angiotensin Receptor Blockers
Antihypertensives, Beta Blockers
Antiinfectives, Miscellaneous
Antiinflammatory, Nonsteroidal Antiinflammatory Drugs (NSAIDs)
Antipsychotics
Antivirals, Antiretrovirals
Antivirals, Hepatitis Agents
Biologic Immunomodulators
Biologics, Miscellaneous (Allergen Immunotherapy)

Bronchodilators, Anticholinergics
Bronchodilators, Steroid Inhalants
Bronchodilators, Sympathomimetics
Calcium Regulators, Osteoporosis
Corticosteroids, Oral
Dermatologics, Acne Products
Dermatologics, Antiinflammatory Agents
Dermatologics, Antipsoriatics
Dermatologics, Scabicides/Pediculocides
Digestive Enzymes
Epinephrine Pens
Estrogens
Fibromyalgia Agents
Gastrointestinal, Antidiarrheals
Gastrointestinal, Antiinflammatory Bowel Agents
Gastrointestinal, Irritable Bowel Syndrome Agents
Gastrointestinal, Proton Pump Inhibitors
Growth Hormones
Hematopoietic, Growth Factors
Migraine Products
Multiple Sclerosis Agents
Multivitamins, Prenatal

Nasal Steroids
Ophthalmics, Adrenergic Agents
Ophthalmics, Antiallergics
Ophthalmics, Antiinfectives
Ophthalmics, Beta Blockers
Ophthalmics, Nonsteroidal Antiinflammatory Drugs (NSAIDs)
Ophthalmics, Prostaglandins
Ophthalmics, Steroids
Otic Antiinfectives
Phosphate Binder Agents
Platelet Aggregation Inhibitors
Pulmonary Hypertension, Phosphodiesterase Inhibitors
Pulmonary Hypertension, Prostaglandin Vasodilators
Pulmonary Hypertension, Endothelin Receptor Antagonists
Smoking Deterrents
Urinary Antispasmodics
Urinary Prostatic Hypertrophy
Vaginal Antiinfectives

This list may change at any time. If a supplemental rebate class is not listed below, the class will be reviewed at the June 4th meeting. In addition, some of the new drugs and supplemental rebate classes listed below may also be moved for review at the June 4th meeting that will be determined by the end of February; thus, these manufacturers can present at the February Manufacturers' Forum and will not need to present again at the April Manufacturers' Forum. Information on the Manufacturers' Forum can be found at <http://dch.georgia.gov/durb-meeting-information>. Please check back frequently for updates.